Edwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023

  • Edwards Lifesciences Corp EW reported Q4 adjusted EPS of $0.64, up 25% Y/Y and higher than the consensus of $0.61.
  • The company reported Q4 revenues of $1.35 billion, up 1% and 7% on constant currency, beating the consensus of $1.33 billion.
  • While TAVR sales remained flat year over year, Edwards reported 1% growth for its structural heart business. It attributed that bump to its Resilia technologies launch and Mitris surgical mitral valve. 
  • Outlook: Edwards Lifesciences reaffirmed its FY23 sales guidance in December 2022 to grow between 9%-12% to $5.6-$6 billion.
  • The company continues to expect the full year 2023 adjusted EPS of $2.45-$2.60.
  • For Q1 FY23, Edwards projects sales of $1.37-$1.45 billion and adjusted EPS of $0.58-$0.64.
  • "We expect meaningful growth and progress in 2023 with a gradual improvement in healthcare staffing and contributions from all major regions," Michael Mussallem, chairman & CEO, said. 
  • Analyst Take: William Blair writes that easing headwinds in 2H of 2023 and a steady stream of commercial catalysts can allow for more robust growth rates and help drive share momentum. The analyst rates the stock as Outperforming.
  • Price Action: EW shares closed higher by 0.84% at $76.70 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsEarnings BeatsLarge CapNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!